Abstracts tagged "prognostic factors and tobacco use"

Abstract Number: 592 • 2015 ACR/ARHP Annual Meeting
The Impact of Tobacco Smoking on the Effectiveness of Abatacept in Rheumatoid Arthritis: Data from a Paneuropean Analysis of RA Registries
Axel Finckh^1,2, Jacques Gottenberg³, M. Victoria Hernández⁴, Florenzo Iannone⁵, Elisabeth Lie⁶, Helena Canhao⁷, Karel Pavelka⁸, Carl Turesson⁹, Merete Lund Hetland¹⁰ and Xavier Mariette¹¹, ¹Rheumatology Division, University Hospital of Geneva, Geneva, Switzerland, ²Div of Rheumatology, University of Geneva, Geneva, Switzerland, ³Hautepierre, Strasbourg, France, ⁴Arthritis Unit, Rheumatology, Hospital Clinic, Barcelona, Spain, ⁵Interdisciplinary Department of Medicine (DIM), Rheumatology Unit, University of Bari, Bari, Italy, ⁶Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ⁷Rheumatology Research Unit, Instituto de Medicina Molecular, Lisbon, Portugal, ⁸Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ⁹Lund University, Rheumatology, Dept. of Clinical Sciences,, Malmö, Sweden, ¹⁰Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Denmark, Glostrup, Denmark, ¹¹Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France
Background/Purpose: It has previously been shown that current smoking is a predictor of poor response to methotrexate or anti-TNF treatment in rheumatoid arthritis (RA). The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].